Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | ADRA2A | P08913 | 4/20 | 0.44 |
| ▸ | ADRA2B | P18089 | 4/20 | 0.44 |
| ▸ | ADRA2C | P18825 | 4/20 | 0.44 |
| ▸ | ADRA1A | P35348 | 4/20 | 0.44 |
| ▸ | ADRA1D | P25100 | 3/20 | 0.44 |
| ▸ | ADRA1B | P35368 | 3/20 | 0.44 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.43 |
| ▸ | SSTR4 | P31391 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4836821 | 0.81 | ALDH1A1 (0.48) | ALDH1A1CYP2C9CYP2C19CYP1A2LMNA | |
| SCHEMBL17782926 | 0.79 | ALDH1A1 (0.50) | ALDH1A1CYP2C9CYP2C19CYP1A2LMNA | |
| SCHEMBL1826565 | 0.79 | ALDH1A1 (0.50) | ALDH1A1CYP2C9CYP2C19CYP1A2LMNA | |
| SCHEMBL4954667 | 0.79 | ALDH1A1 (0.50) | ALDH1A1CYP2C9CYP2C19CYP1A2LMNA | |
| SCHEMBL14376212 | 0.79 | ALDH1A1 (0.50) | ALDH1A1CYP2C9CYP2C19CYP1A2LMNA | |
| SCHEMBL4955989 | 0.79 | ALDH1A1 (0.50) | ALDH1A1CYP2C9CYP2C19CYP1A2LMNA | |
| SCHEMBL888804 | 0.78 | ALOX5 (0.43) | ALDH1A1CYP2C9CYP2C19CYP1A2LMNA | |
| SCHEMBL28564523 | 0.78 | ALDH1A1 (0.49) | ALDH1A1CYP2C9CYP2C19CYP1A2LMNA | |
| SCHEMBL14258602 | 0.77 | KMT2A (0.44) | ALDH1A1CYP2C9CYP2C19CYP1A2ADRA2A | |
| SCHEMBL3048393 | 0.77 | KMT2A (0.46) | ALDH1A1CYP2C9CYP2C19CYP1A2LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7429607-B2 | 5-HT2B receptor antagonists | ASTERAND UK LIMITED (GB) | 2008-09-30 | — | — | US | disclosed |
| US-7429607-B2 | 5-HT2B receptor antagonists | ASTERAND UK LIMITED (GB) | 2008-09-30 | — | — | US | disclosed |
| US-7429607-B2 | 5-HT2B receptor antagonists | ASTERAND UK LIMITED (GB) | 2008-09-30 | — | — | US | disclosed |
| EP-1474140-B1 | 2-OXAZOLAMINES AND THEIR USE AS 5-HT2B RECEPTOR ANTAGONISTS | ASTERAND UK LTD (GB) | 2007-11-21 | — | — | EP | disclosed |
| US-20050176791-A1 | 5-HT2B receptor antagonists | ASTERAND UK LIMITED (GB) | 2005-08-11 | — | — | US | disclosed |
| US-20040010022-A1 | 5-HT2B receptor antagonists | ASTERAND, INC. | 2004-01-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050176791-A1 | 5-HT2B receptor antagonists | HTR2B, HTR1B, HTR3B | ALDH1A1 2700/4885CYP2C9 532/4885CYP2C19 443/4885 |
| US-20040010022-A1 | 5-HT2B receptor antagonists | HTR2B, HTR1B, HTR2C | ALDH1A1 974/4885CYP2C9 326/4885CYP2C19 321/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.